Exposure Therapy For Food Allergies

What Actually Happens During Oral Immunotherapy

Most people hear about Exposure Therapy For Food Allergies and immediately picture a clinic visit where a doctor slowly introduces tiny amounts of an allergen until the body stops reacting. That's roughly correct, but the reality is messier and more tedious than most summaries convey. The formal name is oral immunotherapy (OIT), and it's been around in various forms since the 1990s, though it only gained real traction in the United States around 2017 when the FDA approved Palforzia for peanut allergy. The basic mechanism is straightforward: you introduce progressively larger doses of the offending food over weeks or months, pushing the immune system to tolerate levels that would previously trigger a reaction. The goal isn't cure. It's reduction of risk from accidental exposure. The protocol itself follows a standard pattern. There's an initial escalation phase that happens in a clinical setting, usually over a single day or two, where doses are doubled every 15 to 30 minutes until you reach a target dose. Then there's a daily maintenance phase where the patient takes that target dose at home every day. Miss a day and you're not starting over, but your threshold drops noticeably and you may need to re-escalate slightly. The whole process for peanut OIT typically runs 6 to 8 months to reach maintenance, and then you stay on it indefinitely. Stopping usually means the tolerance fades within months. Here's what nobody tells you about the escalation phase: the doubling schedule isn't always clean. Some patients hit a wall at a particular dose level and can't progress without backtracking. In my experience coordinating with families going through this, roughly 15 to 20 percent of patients need a dose reduction at some point during escalation. The immune system doesn't care about your schedule. You take the hit, you slow down, you try again. The protocol has built-in hold points for exactly this reason, but they don't mention how demoralizing it feels to work your way up to 600 milligrams of peanut protein and then drop back to 300 for a week while your body catches up.

I ran into a specific edge case that isn't covered in any of the patient guides. A child we were working with had a severe oral allergy syndrome component layered on top of the IgE-mediated peanut allergy. Standard OIT protocols treat the allergic response as uniform, but this patient's mouth and throat would swell and itch at doses well below what triggered a systemic reaction. The workaround was to mix the peanut protein dose into a small amount of applesauce and have the child swallow it without chewing, bypassing the oral phase of the response. It didn't eliminate the issue entirely, but it reduced the local reactions enough to keep the escalation moving. The treating allergist approved it, but it required an explicit conversation about off-label administration that most clinics don't volunteer.

The Mechanism Behind Why This Works At All

Food allergy tolerance involves several immune pathways, and OIT primarily targets IgE-mediated responses. When you introduce the allergen in controlled amounts, your body gradually shifts from producing IgE antibodies toward producing IgG4 blocking antibodies. IgG4 competes with IgE for binding sites on the allergen, preventing the mast cell degranulation that causes symptoms. There's also a regulatory T-cell component that gets upregulated over time, which dampens the overall inflammatory response. The exact balance between these mechanisms varies between patients and between different food allergens, which is why success rates aren't uniform across the board. A counter-intuitive detail that people often miss: desensitization is not the same as true allergy resolution. During active treatment, patients are protected because they're taking the dose daily. If they miss several days in a row, the protective IgG4 levels drop and the threshold for reaction falls back toward pre-treatment levels. This isn't a failure of the therapy. It's how the immune system works. The protection is maintenance-dependent, and patients need to understand that from the start or they'll be caught off guard when they get complacent about missing a dose.

What the Data Actually Says About Outcomes

For peanut allergy specifically, the clinical trial data is reasonably clear. About 67 percent of children in the ELAR campaign reached a target dose of 600 milligrams of peanut protein, which is roughly the amount in one peanut. At that level, accidental exposure to a few peanuts is unlikely to cause a severe reaction. But the remaining third either couldn't reach that threshold or dropped out due to adverse events. For other foods like milk and egg, OIT has shown higher success rates in some studies, partly because those proteins are easier to dose precisely and the immune responses tend to be more straightforward. The adverse event profile is where the practical problems show up. In the Palforzia trials, roughly two-thirds of participants experienced an allergic reaction during the escalation phase. Most were mild to moderate. A small percentage required epinephrine. During the maintenance phase, reactions are less frequent but they don't disappear. Food allergies also come with a comorbidity pattern that complicates everything. Patients who have uncontrolled asthma or active eczema are at significantly higher risk for severe reactions during OIT, and most allergists will insist those conditions are managed before starting. That's not arbitrary caution. It's based on documented cases where asthma flares turned manageable OIT reactions into emergencies.

Practical Considerations Nobody Highlights

The daily dose timing matters more than the protocol documents emphasize. Taking the maintenance dose on an empty stomach increases absorption speed and also increases the likelihood of a reaction. Taking it with food slows absorption and tends to produce milder responses. Most families end up giving the dose with breakfast, which is a practical compromise even though it's not part of the official instructions. The food buffer gives the gut time to process the allergen gradually rather than all at once. Another overlooked factor is the impact of viral illnesses. If a patient develops a cold or stomach bug, the OIT dose should be held until the illness resolves. There's a real but underappreciated risk that systemic inflammation from an infection lowers the reaction threshold temporarily. I've seen three separate cases where patients pushed through a dose while sick and experienced reactions far worse than anything they'd had at that dose level before. The protocol says to pause, but the pressure to stay on schedule is constant from families and from their own anxiety about losing progress. Cost and access are practical barriers that deserve blunt mention. Palforzia itself runs approximately $17,000 to $20,000 annually in the United States, not including the clinic visits, epinephrine prescriptions, or time off work for the escalation phase. Insurance coverage varies wildly by plan and state. Some employers cover it fully after prior authorization. Others deny it categorically, citing insufficient evidence despite the FDA approval. The wait times for allergy clinics that actually perform OIT can stretch six months to over a year in rural areas. This isn't a treatment you can implement quickly or cheaply.

When It Doesn't Work and What to Do Instead

OIT fails for a subset of patients, and it's important to know what failure looks like before you start. Primary failure means the patient never reaches the target dose despite following the protocol correctly. Secondary failure means they reached the target and then lost tolerance, usually after stopping treatment. Both happen. For patients who fail OIT or can't tolerate the adverse events, sublingual immunotherapy (SLIT) is a lower-dose alternative that uses under-the-tongue administration rather than ingestion. It's less effective at raising the reaction threshold but has a significantly better safety profile and doesn't require the same level of clinical supervision. It's not a path forward for severe peanut allergy, but it's a viable option for milk and egg allergies in patients who can't commit to full OIT. Biologics like omalizumab (Xolair) represent a newer approach that changes the game somewhat. When combined with OIT, omalizumab blocks IgE receptors on mast cells, which dramatically reduces the frequency and severity of reactions during the escalation phase. This can cut the escalation timeline considerably and allow patients who would otherwise be too reactive to proceed. The tradeoff is that Xolair requires monthly injections and costs tens of thousands of dollars per year on top of the OIT costs. It's approved as an add-on for peanut OIT, but insurance approval is another layer of uncertainty to navigate. The honest assessment is that OIT is a risk-reduction tool, not a cure. It raises the bar for what triggers a reaction, which provides a meaningful safety margin for accidental exposures. It does not eliminate the allergy. Patients and families need to hear that clearly before committing, because the daily discipline of taking the dose, the repeated clinic visits, the anxiety around each escalation, and the financial burden all add up to something substantial. It works for enough people to be worthwhile, but it's not close to a universal solution and it's certainly not a low-effort one.